Codagenix Inc.

Codagenix Inc. is a clinical stage biotechnology company focused on developing vaccine products against influenza, respiratory syncytial virus, dengue virus, and other diseases. The company utilizes a computer-based algorithm called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that closely resemble the wild-type strain at the amino acid level but produce fewer proteins in human cells. This approach results in highly attenuated viruses that serve as effective vaccines or oncolytics against solid tumors, representing a breakthrough in vaccine technology. Founded in 2011 and based in the United States, Codagenix recently secured a $5.88 million grant investment from the U.S. Department of Defense as of 24 October 2023. The company's innovative approach and potential to revolutionize vaccine development make it an intriguing prospect for venture capital firms. With a diverse pipeline targeting various diseases, including COVID, flu, RSV, dengue, yellow fever, breast cancer, and solid tumors, Codagenix poses an exciting investment opportunity in the biotechnology space.